Filing Details

Accession Number:
0001209191-13-044974
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-09-19 20:50:14
Reporting Period:
2013-09-18
Filing Date:
2013-09-19
Accepted Time:
2013-09-19 20:50:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
858803 Avanir Pharmaceuticals Inc. AVNR Pharmaceutical Preparations (2834) 330314804
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1534986 Md Joao Siffert 20 Enterprise,
Suite 200
Aliso Viejo CA 92656
Svp, R&d No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-09-18 21,094 $1.85 137,294 No 4 M Direct
Common Stock Disposition 2013-09-18 21,094 $4.22 116,200 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2013-09-18 21,094 $0.00 21,094 $1.85
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
35,156 2021-12-15 No 4 M Direct
Footnotes
  1. Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting Person, which are subject to certain vesting conditions.
  2. The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. A portion of the proceeds from the sale will be used to pay required tax withholdings due upon the vesting of Restricted Stock Units granted to the Reporting Person. Following the sales reported on this Form 4, the Reporting Person has a total of 133,516 options to purchase shares of common stock that are vested and immediately exercisable and a total of 236,640 options to purchase shares of common stock that have not yet vested. Following the sales reported on this Form 4, the Reporting Person also has 104,600 unvested Restricted Stock Units, of which 50,905 are performance-based Restricted Stock Units.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.16 to $4.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. The option was granted on 12/15/2011 and vests with respect to one-quarter of the underlying shares upon the first anniversary of the grant date, and then with respect to the remaining shares quarterly thereafter over the next three years.